AbbVie Inc. (ABBV) Stock-Based Compensation
The stock-based comp for AbbVie Inc. (ABBV) is $955.00 Million with a year-over-year change of +4.83%. Stock-Based Compensation (SBC) is the expense recognized for equity awards (stock options, RSUs) granted to employees. It's a non-cash expense that dilutes existing shareholders.
ABBV Stock-Based Comp Chart
Current Stock-Based Comp
$955.00M
$955.00 Million
Year-over-Year Change
+4.83%
vs. $911.00M prior year
Historical Data
17
Years of data available
Annual Stock-Based Comp History
| Year | Stock-Based Comp | YoY Change | % Change |
|---|---|---|---|
| 2025 | $955.00M | +$44.00M | +4.83% |
| 2024 | $911.00M | +$164.00M | +21.95% |
| 2023 | $747.00M | +$76.00M | +11.33% |
| 2022 | $671.00M | $-21.00M | -3.03% |
| 2021 | $692.00M | $-61.00M | -8.10% |
| 2020 | $753.00M | +$323.00M | +75.12% |
| 2019 | $430.00M | +$9.00M | +2.14% |
| 2018 | $421.00M | +$56.00M | +15.34% |
| 2017 | $365.00M | +$12.00M | +3.40% |
| 2016 | $353.00M | +$71.00M | +25.18% |
| 2015 | $282.00M | +$41.00M | +17.01% |
| 2014 | $241.00M | +$29.00M | +13.68% |
| 2013 | $212.00M | +$25.00M | +13.37% |
| 2012 | $187.00M | +$24.02M | +14.74% |
| 2011 | $162.98M | $-4.02M | -2.41% |
| 2010 | $167.00M | +$10.28M | +6.56% |
| 2009 | $156.72M | — | — |
Related Metrics
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael